共 429 条
[1]
Auliac JB(2019)Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation Lung Cancer 127 96-102
[2]
Pérol M(2016)Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity Clin Cancer Res 22 5130-5140
[3]
Planchard D(2016)Acquired resistance to first-line afatinib and the challenges of prearranged progression biopsies J Thorac Oncol 11 2022-2026
[4]
Monnet I(2020)Clinical factors affecting the response to osimertinib in non-small cell lung cancer patients with an acquired epidermal growth factor receptor T790M mutation: a long-term survival analysis Target Oncol 15 337-345
[5]
Wislez M(2014)AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer Cancer Discov 4 1046-1061
[6]
Doubre H(2018)The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response Br J Cancer 119 1252-1258
[7]
Guisier F(2016)Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study Lancet Oncol 17 1643-1652
[8]
Pichon E(2020)Analysis of lung adenocarcinoma with bone metastasis: a case report Transl Lung Cancer Res 9 389-392
[9]
Greillier L(2021)The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M Sci Rep 11 12084-4892
[10]
Mastroianni B(2019)Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study Cancer Manag Res 11 4883-59